Details of the Drug

General Information of Drug (ID: DMTW3R8)

Drug Name
Sulfadiazine
Synonyms
Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ
Indication
Disease Entry ICD 11 Status REF
Rheumatic fever 1B40-1B42 Approved [1]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 250.28
Topological Polar Surface Area (xlogp) -0.1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [2]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.55 mL/min/kg [4]
Elimination
57% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 684.94708 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.44% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.29 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.13 mg/mL [2]
Chemical Identifiers
Formula
C10H10N4O2S
IUPAC Name
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Canonical SMILES
C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
InChI
InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
InChIKey
SEEPANYCNGTZFQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5215
ChEBI ID
CHEBI:9328
CAS Number
68-35-9
DrugBank ID
DB00359
TTD ID
D05LKP
INTEDE ID
DR1509
ACDINA ID
D00642

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Dihydropteroate synthetase (Bact folP) TT4ILYC DHPS_ECOLI Inhibitor [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]
RNA cytidine acetyltransferase (hALP) DEZV4AP NAT10_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sulfadiazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [62]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Repaglinide. Acute diabete complication [5A2Y] [63]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Tolazamide. Acute diabete complication [5A2Y] [63]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Nateglinide. Acute diabete complication [5A2Y] [63]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin-glulisine. Acute diabete complication [5A2Y] [63]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Acetohexamide. Acute diabete complication [5A2Y] [63]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin-aspart. Acute diabete complication [5A2Y] [64]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Glipizide. Acute diabete complication [5A2Y] [63]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [65]
Montelukast DMD157S Moderate Decreased metabolism of Sulfadiazine caused by Montelukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [66]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Sulfadiazine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [67]
Anisindione DM2C48U Major Increased plasma concentration of Sulfadiazine and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [68]
Mycophenolic acid DMU65NK Moderate Altered absorption of Sulfadiazine due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [69]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Cannabidiol. Epileptic encephalopathy [8A62] [70]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [71]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [72]
Etravirine DMGV8QU Moderate Decreased metabolism of Sulfadiazine caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sulfadiazine and Mipomersen. Hyper-lipoproteinaemia [5C80] [74]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sulfadiazine and BMS-201038. Hyper-lipoproteinaemia [5C80] [75]
Lesinurad DMUR64T Moderate Decreased metabolism of Sulfadiazine caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [76]
Methotrexate DM2TEOL Moderate Increased plasma concentration of Sulfadiazine and Methotrexate due to competitive binding of plasma proteins. Leukaemia [2A60-2B33] [77]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Sulfadiazine and Porfimer Sodium. Lung cancer [2C25] [78]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [79]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Idelalisib. Mature B-cell leukaemia [2A82] [80]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Clofarabine. Mature B-cell lymphoma [2A85] [81]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Sulfadiazine and Methoxsalen. Mycosis fungoides [2B01] [62]
Diclofenac DMPIHLS Moderate Decreased metabolism of Sulfadiazine caused by Diclofenac mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [62]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Sulfadiazine and Prilocaine. Pain [MG30-MG3Z] [82]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Sulfadiazine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [83]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Sulfadiazine and Verteporfin. Psoriasis [EA90] [70]
Celecoxib DM6LOQU Moderate Decreased metabolism of Sulfadiazine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [84]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Sulfadiazine caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [85]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [70]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [62]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Sulfadiazine and Naltrexone. Substance abuse [6C40] [86]
Warfarin DMJYCVW Major Increased plasma concentration of Sulfadiazine and Warfarin due to competitive binding of plasma proteins. Supraventricular tachyarrhythmia [BC81] [68]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Sulfadiazine due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [69]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Tolbutamide. Type 2 diabetes mellitus [5A11] [63]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Chlorpropamide. Type 2 diabetes mellitus [5A11] [63]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [63]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Sulfadiazine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [63]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Sulfadiazine and Ganciclovir. Virus infection [1A24-1D9Z] [62]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Sulfadiazine and Valganciclovir. Virus infection [1A24-1D9Z] [62]
⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Docusate sodium E00563 23673837 Surfactant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sulfadiazine 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
9 Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
10 Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
21 A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
22 Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
23 Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
24 Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
25 NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
26 Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
27 Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
28 Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
29 Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
30 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
31 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
32 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
33 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
34 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
35 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
36 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
37 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
38 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
39 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
40 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
41 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
42 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
43 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
44 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
45 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
46 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
47 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
48 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
49 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
50 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
51 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
52 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
53 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
54 In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
55 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
56 Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
57 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
58 Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
59 A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
60 Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.
61 Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57.
62 Cerner Multum, Inc. "Australian Product Information.".
63 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
64 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
65 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
66 Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
67 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
68 Cook DE, Ponte CD "Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia." J Fam Pract 39 (1994): 589-91. [PMID: 7798864]
69 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
70 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
71 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
72 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
73 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
74 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
75 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
76 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77 Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J "Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis." Clin Pharmacokinet 30 (1996): 194-210. [PMID: 8882301]
78 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
79 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
80 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
81 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
82 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
83 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
84 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
85 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
86 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.